Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Ephedra adverse events

This article was originally published in The Tan Sheet

Executive Summary

Nearly 75% of dietary supplement-related adverse event reports collected during a six-month period in California occurred in patients who ingested ephedrine alkaloid-containing products, a study in the American Journal of Health-System Pharmacy finds. The findings were based on AEs reported to the California Poison Control System between April 2002 and September 2002. Of 480 supplement-related AEs, 353 involved patients who took ephedra products, Cathi Dennehy, University of California, San Francisco, et al., find. The multiple-ingredient products that were "most frequently involved in severe reactions" were Hydroxycut, Metabolife, Xenadrine, Stacker 2 and Yellow Jackets, the authors add. FDA currently is appealing an April 13 Utah federal court decision that overturned the agency's 2004 ban on ephedra for low-dose products...
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS098503

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel